We would like to hear from you! Please call Gary Pittman Jr at 512-637-0373 or email garypjr@pcinews.com.
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced observational data from 8 years of clinical practice showing that the company’s oral Factor Xa inhibitor Xarelto (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a
Stryker announced FDA 510(k) clearance of the Target Tetra detachable coil, the latest addition to the company’s Target platform. The Target Tetra device, which is specifically designed to treat small aneurysms, combines a new tetrahedral shape and softness level. According to the company, the delicate nature of small aneurysms makes
We would like to hear from you! Please call Gary Pittman Jr at 512-637-0373 or email garypjr@pcinews.com.
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced observational data from 8 years of clinical practice showing that the company’s oral Factor Xa inhibitor Xarelto (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a
We would like to hear from you! Please call Gary Pittman Jr at 512-637-0373 or email garypjr@pcinews.com.
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced observational data from 8 years of clinical practice showing that the company’s oral Factor Xa inhibitor Xarelto (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a
Stryker announced FDA 510(k) clearance of the Target Tetra detachable coil, the latest addition to the company’s Target platform. The Target Tetra device, which is specifically designed to treat small aneurysms, combines a new tetrahedral shape and softness level. According to the company, the delicate nature of small aneurysms makes
Corindus, a Siemens Healthineers Company, announced it has been rebranded to Siemens Healthineers Endovascular Robotics, a dedicated business within the Advanced Therapies area of Siemens Healthineers. The aim of the Endovascular Robotics business is to advance interventions with robotics and change the way that care is delivered through innovations that
Cook Medical announced the appointment of John A. Kaufman, MD, MS, as Chief Medical Officer (CMO), effective July 2023. Currently, Dr. Kaufman is the inaugural Chair of the Dotter Department of Interventional Radiology, Director of the Dotter Interventional Institute, and Frederick S. Keller Professor of Interventional Radiology at the Oregon
Merit Medical Systems, Inc. announced the enrollment of the first patient in the company’s prospective, observational study of EmboCube embolization gelatin to control bleeding or hemorrhage. The EmboCube Embolization Gelatin study is designed to enroll 100 patients across multiple centers in Australia and France. The company advised that EmboCube is
We would like to hear from you! Please call Gary Pittman Jr at 512-637-0373 or email garypjr@pcinews.com.
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced observational data from 8 years of clinical practice showing that the company’s oral Factor Xa inhibitor Xarelto (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a
Stryker announced FDA 510(k) clearance of the Target Tetra detachable coil, the latest addition to the company’s Target platform. The Target Tetra device, which is specifically designed to treat small aneurysms, combines a new tetrahedral shape and softness level. According to the company, the delicate nature of small aneurysms makes
You can place any content here, including Advertising. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque scelerisque lectus nec est feugiat, at eleifend sapien suscipit. Cras in neque ac nulla blandit auctor sed ut purus. Curabitur metus elit, tristique id auctor a, fermentum imperdiet felis. Maecenas imperdiet facilisis nibh at viverra. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Cras euismod rhoncus nibh, et vestibulum justo bibendum et. Quisque sed vehicula erat. Nulla cursus a nisi a tincidunt. Curabitur pulvinar, urna quis volutpat dignissim, libero est fermentum mauris, ut rutrum metus lacus at ipsum. Donec rhoncus leo eget dolor gravida ullamcorper. Suspendisse tempus, velit condimentum hendrerit ultrices, tellus libero auctor leo, non feugiat libero dui a tellus.